Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

PSNL US Equity

Personalis, Inc.Health Care · Services-Medical Laboratories · CIK 1527753 · FY ends Dec 31
$13.91
+0.02 (+0.14%)
USD · as of 2026-08-18 · marketstack
1 registered study · 1 active

Studies where PSNL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 observational

Held by 12 tracked-famous managers (JANE STREET GROUP, LLC, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, TWO SIGMA INVESTMENTS, LP, +7 more) · FINRA short interest 1.7 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 7 sells · government filings 180d: none disclosed

StudyPhaseStatusConditionsEnrollmentPrimary completionUpdated
CtDNA Based MRD Testing for NAC Monitoring in TNBCNCT06230185observationalEvaluate the correlation of MRD to pCR after NAC in TNBCRecruitingTNBC - Triple-Negative Breast Cancer, Minimal Residual Disease4222025-08-302025-01-07

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19